Visual function and long-term chloroquine treatment.
Ophthalmic examinations and selected tests of visual function were performed on 64 patients with rheumatoid arthritis who had received daily doses of 200 mg chloroquine sulphate for periods ranging from 3 to 11 months. Visual fields were determined by Humphrey automated perimetry and Amsler grids and a further battery of four tests of macular function (visual evoked potentials, critical flicker fusion threshold, Cambridge contrast sensitivity and the macular dazzle test) were administered. No case of retinal pigmentary abnormalities plus visual loss was found, but 2 patients were advised to cease chloroquine therapy on the basis of funduscopic findings. A small group of patients with relatively poor scores on one or more tests had normal visual fields and ophthalmic findings. There were no significant partial correlations between test results and the cumulative dose of chloroquine. These results support the opinion that currently recommended doses of chloroquine pose a minimal risk of retinal toxicity.
Bartel
P R
PR
Department of Neurology, University of Pretoria.
Roux
P
P
Robinson
E
E
Anderson
I F
IF
Brighton
S W
SW
van der Hoven
H J
HJ
Becker
P J
PJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002648:Child; D002738:Chloroquine / Q000008:administration & dosage / Q000009:adverse effects*; D003118:Color Perception / Q000187:drug effects; D005260:Female; D006801:Humans; D008266:Macula Lutea / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014786:Vision Disorders / Q000139:chemically induced*; D014794:Visual Fields / Q000187:drug effects
D002738:Chloroquine